Archish Kataria, MD
Gastroenterology · Albuquerque, NMNPI 1437530045
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,487 of the $3,524 with a category attached, or 70.6%. 20 manufacturers reported payments, led by Olympus Corporation Of The Americas at 28.6% of the total. 2025 is the largest year on record at $1,257, more than ten times the $118 reported in 2020.
Across 121 payments — averaging $29.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$1K
- AbbVie$794
- Johnson & Johnson$425
- Takeda Pharmaceuticals U.S.A., Inc.$244
- Intercept Pharmaceuticals, Inc.$164
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$141
- plus $746 from 14 others
What the payments were for
- Travel & lodging$97128%
- Food & beverage$2,48771%
- Education$652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 11 | $1,009 |
| AbbVie | 35 | $794 |
| Johnson & Johnson | 21 | $425 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $244 |
| Intercept Pharmaceuticals, Inc. | 4 | $164 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $141 |
| Olympus America Inc. | 5 | $138 |
| AstraZeneca | 1 | $117 |
| Bristol Myers Squibb | 5 | $85 |
| Ardelyx, Inc. | 4 | $80 |
| Pfizer | 3 | $65 |
| Daiichi Sankyo Inc. | 4 | $62 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Medtronic | 1 | $33 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Sanofi | 2 | $31 |
| Ambu Inc. | 1 | $23 |
| Digestive Care, Inc. | 1 | $19 |
| Boston Scientific | 1 | $15 |
| Endogastric Solutions, Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DISPOSABLE DISTAL ATTACHMENT$861
- Olympus$861
- Single Use Electrosurgical Knife KD-655$756
- OCALIVA$121
- Creon$118
- ANDEXXA$117
How this compares
$3,524 in reported general payments places this provider in the 70th percentile of 81 gastroenterology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 11 | $306,298 |
| XifaxanRifaximin | 21 | $64,943 |
| LinzessLinaclotide | 54 | $44,677 |
| CreonLipase/Protease/Amylase | 14 | $37,331 |
| Mesalamine | 28 | $13,890 |
| Budesonide DrBudesonide | 28 | $2,625 |
| Omeprazole | 146 | $1,756 |
| Sucralfate | 34 | $1,670 |
| Esomeprazole Magnesium | 39 | $1,584 |
| CholestyramineCholestyramine (With Sugar) | 41 | $1,540 |
| Lansoprazole | 26 | $1,288 |
| Lubiprostone | 11 | $1,057 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 49 | $945 |
| Pantoprazole Sodium | 55 | $760 |
| Ondansetron OdtOndansetron | 17 | $693 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $425 | $306,29811 claims |
| AbbVieLinzess, Creon | $794 | $82,00868 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $141 | $64,94321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 81 gastroenterology providers in New Mexico.
Other gastroenterology in Albuquerque
- Antoine JakicheAlbuquerque$108K
- Fazia MirAlbuquerque$98K
- Christopher ChangAlbuquerque$51K
- Stuart WeismanAlbuquerque$19K
- Denis McCarthyAlbuquerque$17K
- Andrei GasicAlbuquerque$9K
- Amal ShineAlbuquerque$7K
- Julie FarrerAlbuquerque$7K
- Zachary NeubertAlbuquerque$5K
- Jessica RyderAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.